Drug Profile
CAT 2054
Alternative Names: CAT-2054; Eicosapentaenoic acid-niacin conjugate (CAT 2054); Niacin-eicosapentaenoic acid conjugate (CAT 2054)Latest Information Update: 09 Sep 2021
Price :
$50
*
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics
- Class Antihyperlipidaemics; Eicosanoids; Nicotinic acids; Omega 3 fatty acids; Peripheral vasodilators; Small molecules; Vitamins
- Mechanism of Action Sterol regulatory element binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
- 23 Oct 2018 Discontinued - Phase-II for Hypercholesterolaemia (Combination therapy) in USA (PO)
- 30 Jun 2016 Catabasis completes its phase IIa trial for Hypercholesterolaemia in USA (NCT02608697)